tirzepatide pots for Weight Loss Understanding POTS Syndrome Treatment Options

Contraindications Tirzepatide, whether compounded or brand-name, should not be used by individuals with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, severe gastroparesis or gastrointestinal disease, or during pregnancy

In SURPASS 1, a 40-week trial of tirzepatide compared to placebo, tirzepatide therapy reduced hemoglobin A1c by 1.87, 1.89, 2.07% for 5 mg, 10 mg, or 15 mg doses, respectively

These effects relate directly to growth hormone elevation and typically resolve with dose adjustment

Months 46 Consistent fat reduction

Reconstitution Vial strength 3.33 mg Bacteriostatic water 3 mL Concentration 1.11 mg/mL 1 unit = 0.01 mL = 11.1 mcg 1Draw 3.0 mL of bacteriostatic water using a sterile syringe

National Institute on Aging